Featured Clinical Trials
Learn what’s coming down the research pipeline, and find breast cancer clinical trials you may be eligible to participate in.
Researchers seek participants with early-stage, HER2-positive breast cancer for a phase III study. The trial team will explore which of two anti-HER2 medicines results in the longest invasive disease-free survival.
Researchers seek 48 women for a small, phase IB study of ONT-380, a new anti-HER2 medicine that can be taken by mouth. The pill will be given along with the standard amount of T-DM1, by vein.
Researchers seek postmenopausal women with hormone-positive breast cancer for a clinical trial exploring whether daily doses of an antidepressant lessens pain related to the use of hormonal therapies, when compared to women who take no pain medicines.
Researchers seek women diagnosed with invasive, early-stage, hormone-positive breast cancer to enroll in a phase III study.
The BROCADE study needs men and women with metastatic breast cancer and a BRCA1 or BRCA2 gene mutation for a phase II clinical trial. The trial team will assess how safe and effective a new targeted therapy is when combined with one or more common chemotherapy medicines.
Researchers seek 240 women with metastatic, triple-negative breast cancer for a phase II study assessing the safety of different chemotherapy combinations and how well they prevent the worsening of the disease.
Postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that continued to grow during or after treatment with an aromatase inhibitor (anastrozole, letrozole, and exemestane) are needed for a clinical trial. Researchers conducting the trial are examining the safety and effectiveness of combining the PI3K inhibitor BMK120 with fulvestrant (Faslodex).
Baltimore-based researchers seek participants with metastatic breast cancer for a phase II trial comparing a combination of chemotherapy plus a cancer vaccine with or without trastuzumab.
Researchers are recruiting 700 women with HER2-negative breast cancer for an international clinical trail assessing disease-free survival (DFS), the length of time during which participants show no signs of cancer, when treated with NeuVax, a cancer vaccine designed to prevent or delay disease recurrence.
A study for women with early-stage breast cancer removed by lumpectomy compares the safety and effectiveness of a more rapid course of radiation with standard therapy.